A group of China-based investors is backing Bioatla LLC's bid to address growing demand for new immunotherapies in the country with a $30 million equity buy-in. Bioatla President, CEO and Chairman Jay Short called it a "transformative event" that will help the company leverage expertise at its established Beijing lab to build new strategic partnerships with Chinese biophama companies in pursuit of further developing its conditionally active biologic (CAB) antibody platform and other technologies.